During the past 20 years, hundreds of thousands of women with breast cancer have taken the drug Herceptin, typically for a year or more. The medicine, used to treat an aggressive form of the disease, ...
– At three years, 88.3 percent of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared to 77.0 percent treated with ...
High TILs may predict which patients with early HER2-positive breast cancer may have a reduced risk for disease relapse or death with Herceptin treatment. High tumor infiltrating lymphocytes (TILs) in ...
A recent study provided new evidence about the effect that the entry of biosimilars has on lowering the price of cancer treatments covered by Medicare. The study, published in the Journal of Clinical ...
The Food and Drug Administration (FDA) approved Tukysa (tucatinib) plus Herceptin (trastuzumab) for the treatment of patients with previously treated HER2-positive metastatic colorectal cancer, ...
Hercessi is supplied as a 150mg lyophilized powder in a single-dose vial for intravenous infusion after reconstitution. The approval of Hercessi was based on a comprehensive package of analytical, ...
ZURICH (Reuters) - Roche Holding AG's Herceptin combined with Pertuzumab showed "impressive results" in a Phase II breast cancer trial, the Swiss drugmaker said on Friday. For the Roche statement, ...
Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz ...
LONDON (Reuters) - British group GlaxoSmithKline has pulled a U.S. application seeking approval to use its breast cancer drug Tykerb in combination with Roche's rival product Herception for certain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback